Takara Bio

Takara Bio Home

Takara Bio USA Inc provides kits reagents instruments and services that help researchers explore questions about gene discovery regulation and function As a member of the Takara Bio Group TBUSA is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology

RetroNectin Gene Therapy TAKARA BIO INC

The birth of RetroNectin Takara Bio in collaboration with Indiana University in the United States discovered that a recombinant human fibronectin fragment RetroNectin dramatically enhanced the efficiency of the gene transduction into hematopoietic stem cells by retrovirus vectors Nature Medicine 1996 This big discovery broke the major premise that it is impossible to transduce

TAKARA BIO INC

Takara Bio is committed to working for the benefit of society through the use of biotechnology and Gene medicine developed from our research to enrich people s health and lives

Takara Bio

Takara Bio has developed one step probe RT qPCR kits that are currently being used in the Chinese CDC and the Japanese NIID protocols for COVID 19 detection Detection of inactivated influenza virus Flu A H1N1 Inactivated influenza virus was spiked to oropharyngeal swab nasopharyngeal swab and sputum at the concentration of 2 x 10 0 10 2

Takara Bio to Acquire Clontech Unit of BD Biosciences

Takara Bio Inc announced that it has entered into a definitive agreement to acquire the Clontech unit Clontech of BD Biosciences mainly consisting of Clontech Laboratories Inc employees 190 for USD 60 million adjusted from USD 65 million due to the retention of certain inventories and receivables by the seller from BD

Gene Therapy TAKARA BIO INC

Takara Bio to Present Clinical Data of Oncolytic Virus C REV and NY ESO 1 siTCR Gene Therapy at ASCO 2019 Click here for the detail > News Release 2019/05/16 Marketing Authorization Application for Oncolytic Virus Immunotherapy C REV for Unresectable or Metastatic Melanoma Submitted in Japan

Gene Therapy TAKARA BIO INC

Gene Therapy TAKARA BIO INC Clinical program for NY ESO 1 siTCR gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine

Takara Bio Japan

The fully automated Rheonix NGS OnePrep solution streamlined NGS library preparation for the new Takara Bio ThruPLEX Tag Seq HV kit for Pan Cancer targeted sequencing Molecularly tagged sample

Takara Bio

Takara Bio Webinar Seamless Cloning without compromiseDiscover In Fusion Download now Watch our webinar to learn how to build any construct without compromise using In Fusion HD Cloning Plus Sequence independent do not be limited by available restriction sites Clone ANY insert into ANY vector at ANY locus

Takara Bio USA Inc LinkedIn

Takara Bio USA Inc 7 435 followers on LinkedIn Takara Bio USA Inc formerly Clontech Laboratories Inc a Takara Bio company develops manufactures and distributes a wide range of life

Takara Bio product citation finder

Takara Bio USA Inc provides kits reagents instruments and services that help researchers explore questions about gene discovery regulation and function As a member of the Takara Bio Group TBUSA is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology

Takara Bio Inc LinkedIn

Takara Bio Inc 2 339 followers on LinkedIn Takara Bio Inc is committed to improving the human condition through biotechnology Starting as the biomedical business of Takara Shuzo a

Takara Bio s Center for Gene and Cell Therapy Processing

Location of Takara Bio s Center for Gene and Cell Therapy Processing II Center for Gene and Cell Therapy Processing II is located in Nojihigashi Kusatsu Shiga West Japan The facility occupies a gross floor area of 14 500m² and is more than double the size of an existing facility at the location Approximately 4 600m² of the total floor

Takara BioCrunchbase Company Profile Funding

Takara Bio Inc develops manufactures and distributes a wide range of life science reagents and kits under the Takara Clontech and Cellartis brands Key products include SMART cDNA synthesis kits for a variety of samples and applications including NGS high performance qPCR and PCR reagents including the Takara Ex Taq Takara

Takara Bio to Support Development of Novel Coronavirus

Kusatsu/Shiga Japan –March 5 2020Takara Bio Inc Takara Bio announced that it has a supportive role in developing prophylactic DNA vaccine against novel Coronavirus SARS CoV 2 with the advantage of technology for manufacturing plasmid DNA undertaken by a group comprising Dr Ryuichi Morishita Professor of Department of Clinical Gene Therapy Graduate School of Medicine

Takara Bio Inc Contact Information Biocompare

Takara Bio USA Inc TBUSA a wholly owned subsidiary of Takara Bio Inc is committed to helping scientists break new ground with innovative technologies for the life sciences Our extensive portfolio of reagents instruments and services supports advancements across many areas of research development frontline diagnostics and clinical

CanerpaturevTakara BioAdisInsight

Canerpaturev is an oncolytic attenuated spontaneous mutant of herpes simplex virus type 1 HSV1 being developed by Takara Bio for the treatment of cancer

Takara Bio Europe S A S Saint Germain en Laye France

Takara Bio s portfolio supports applications including NGS gene discovery regulation and function studies as well as genetic analysis protein expression and purification gene editing stem cell studies and plant and food research Request information now Add company to watchlist Recommend company

Contact Us Corporate Guide TAKARA BIO INC

Takara Bio is committed to working for the benefit of society through the use of biotechnology and Gene medicine developed from our research to enrich people s health and lives

Takara Bio

Takara Bio Europe Dr Matthieu Pesant has been the European NGS Product Manager at Takara Bio Europe since 2017 and manages Takara s RNA seq and DNA seq product range including the market leading single cell NGS technologies SMART Seq and SMARTer PicoPLEX

Takara Bio enters into a license and supply agreement of

About Takara Bio Inc Takara Bio Inc a world leader in biotechnology research and development offers a host of life science research solutions from enzymes and GMP grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent a world standard in gene therapy protocols

Takara Bio Good Gene Cellular and Tissue based Products Manufacturing Practice GCTP /Good Manufacturing Practice GMP Cell Bank 20155Takara Bio

Takara Bio to Support Development of Novel Coronavirus

Kusatsu/Shiga Japan –March 5 2020Takara Bio Inc Takara Bio announced that it has a supportive role in developing prophylactic DNA vaccine against novel Coronavirus SARS CoV 2 with the advantage of technology for manufacturing plasmid DNA undertaken by a group comprising Dr Ryuichi Morishita Professor of Department of Clinical Gene Therapy Graduate School of Medicine

Takara Bio Inc

Takara Bio Inc is committed to improving the human condition through biotechnology Starting as the biomedical business of Takara Shuzo a fermentation and beverage company founded in 1925 now Takara Holdings Company Inc Takara Bio has focused on developing research tools for the life sciences cell and gene therapy technologies and nutraceuticals since its launch in 1967

Takara Bio to mass produce COVID 19 vaccine candidate

Takara Bio to mass produce COVID 19 vaccine candidate TOKYO Japanese biotech company Takara Bio plans to mass produce novel coronavirus vaccinations as early as this year President and CEO

Takara Bio to mass produce COVID 19 vaccine candidate

TOKYO Japanese biotech company Takara Bio plans to mass produce novel coronavirus vaccinations as early as this year President and CEO Koichi Nakao told Nikkei in

Takara Bio to mass produce COVID 19 vaccine candidate

Takara Bio to mass produce COVID 19 vaccine candidate TOKYO Japanese biotech company Takara Bio plans to mass produce novel coronavirus vaccinations as early as this year President and CEO